Buy Foster® spray can 0.1 mg + 6 mcg/dose, 120 doses
  • Buy Foster® spray can 0.1 mg + 6 mcg/dose, 120 doses


Chiesi Pharmaceutical SpA
1004 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Foster has an anti-inflammatory effect, reduces the severity of symptoms of bronchial asthma and reduces the frequency of exacerbations of the disease, while having a lower incidence of side effects than systemic GCS.


Basic therapy of bronchial asthma, providing for the appointment of a combination therapy (inhaled glucocorticosteroid and β 2 long-acting adrenergic mimic):
Patients whose symptoms are ill-controlled by inhaled glucocorticosteroids and β 2 short-acting adrenergic mimetics.
Patients receiving effective maintenance doses of inhaled glucocorticosteroids and long-acting β 2 adrenergic mimetics.


1 dose contains beclomethasone dipropionate 100 μg, formoterol fumarate 6 μg.

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

Selection of the dose of drugs that are part of Foster, occurs individually and depending on the severity of the disease. For adults and adolescents over 12 years old: 1-2 inhalations twice a day. Patients should be under the constant supervision of a physician for an adequate selection of the Foster dose. The dose should be reduced to the lowest, against which the optimal control of the symptoms of bronchial asthma is maintained. When achieving complete control over the symptoms of bronchial asthma on the background of the minimum recommended dose of the drug, in the next step, you can try the appointment of monotherapy with inhaled glucocorticosteroids.
There is no need for a special selection of the dose of the drug for elderly patients.

Adverse reactions

Among the most frequent side effects associated with formoterol, described are typical for beta2-adrenergic mimics, such as: hypokalemia, headache, tremor, palpitations, cough, muscle cramps, lengthening of the QTc interval. Side effects characteristic of beclomethasone dipropionate: candidiasis of the mucous membrane of the mouth and pharynx, irritation in the throat.
Like other inhalants, Foster can cause paradoxical bronchospasm.
Other side effects characteristic of formoterol thrombocytopenia, angioneurotic edema, hyperglycemia, increased blood levels of insulin, free fatty acids, glycerol and ketone derivatives, sleep disorders, hallucination, fatigue, restlessness, changes in taste (dysgeusia), tachycardia, tachyarrhythmia, ventricular premature beats, angina (ischemic heart disease), atrial fibrillation, arterial hypertension, arterial hypotension, exacerbation of bronchial asthma, shortness of breath, nausea, itching, skin rash, urticaria, hyperhidrosis, myalgia, nephritis, peripheral edema.


Hypersensitivity to Foster components, children under 12 years old.
Pregnancy, lactation period, pulmonary tuberculosis, fungal, viral or bacterial respiratory infections, thyrotoxicosis, artificial hypothyroidism, artificial hypothyroidism; diseases (acute myocardial infarction, ischemic heart disease, tachyarrhythmia, decompensated chronic heart failure, prolonged nd Q-Tc interval (reception formoterol can cause elongation QTs- interval)).

Drug interactions

Β-adrenergic receptor blockers may weaken the action of formoterol. Foster should not be administered simultaneously with b-adrenoblockers (including eye drops), except in forced cases.

Pregnancy and Lactation

There is no clinical data on the use of Foster during pregnancy. No embryotoxic or teratogenic effects have been identified in animal studies.

In pregnancy, Foster should be used only in cases where the benefits of the drug outweigh the potential risk to the fetus. It is recommended to prescribe a minimum dose that provides effective control of symptoms of bronchial asthma.

There is no data on the penetration of Foster into the breast milk of women. Foster can be prescribed to lactating women only in cases where the expected therapeutic effect for the mother outweighs the potential risk to the baby.

Special instructions

It is recommended to instruct the patient about the need to rinse the mouth with water after inhalation of maintenance doses in order to prevent the risk of developing candidiasis of the mucous membrane of the oral cavity and pharynx.

The balloon is under pressure: do not expose to heat, do not pierce, do not throw into the fire, even empty. Use within 3 months from the start of use.


Symptoms: overdose occurs typical of beta2adrenomimetic symptoms of formoterol, such as nausea, vomiting, headache, tremor, drowsiness, heart palpitations, tachycardia, ventricular arrhythmia, prolongation of the QTc interval, metabolic acidosis, hypokalemia, hyperglycemia.

Treatment: symptomatic treatment. In severe cases, hospitalization. The use of cardioselective beta-blockers may be considered with caution, since the use of these agents may cause bronchospasm. It is necessary to monitor the level of potassium in the blood plasma.

Inhalation of higher doses of beclomethasone dipropionate may cause a temporary inhibition of the function of the adrenal cortex. Usually this does not require any emergency measures, since in most cases the normal function of the adrenal glands is restored within a few days. It is recommended to monitor the level of cortisol in the blood plasma.

In case of chronic intake of excessive doses of beclomethasone dipropionate, its systemic effect may manifest itself: a significant inhibition of the adrenal cortex can occur up to the adrenal crisis. Acute adrenal crisis is manifested by hypoglycemia, accompanied by confusion and / or convulsions. The situations that can serve as trigger factors for acute adrenal crisis include trauma, surgery, infection, or a rapid reduction in the dose of beclomethasone, which is part of Foster. In chronic overdose, it is recommended to monitor the reserve function of the adrenal cortex.

  • Brand name: Foster
  • Active ingredient: Beclomethasone, Formoterol
  • Dosage form: Aerosol for inhalation dosed.
  • Manufacturer: Chiesi Pharmaceutical SpA
  • Country of Origin: Italy

Studies and clinical trials of Foster (Click to expand)

  1. Foster UG (1996): Letter to the editor: Academicians are more likely to share each other's toothbrush than each other's nomenclature [Cohen, 1982]. Am J Med Genet 66:471-474
  2. Photodynamic modulation of wound healing with BPD-MA and CASP
  3. Care of terminally ill children with cancer
  4. Technologies for ubiquitous supercomputing: a Java interface to the Nexus communication system
  5. Software infrastructure for the I-WAY metacomputing experiment
  6. Measurement of Markers of Osteoclast and Osteoblast Activity in Patients with Acute and Chronic Diabetic Charcot Neuroarthropathy
  7. The impact of weather patterns on historic and contemporary catchment sediment yields
  8. Book Review: Material Fluxes on the Surface of the Earth edited for the National Research Council, National Academy Press, Washington, 1994. No. of pages: xiv + 170, Price: £32.95. ISBN 0-309-04745-5; Book Review: Variability in Stream Erosion and Sediment Transport edited by L. J. Olive, R. J. Loughran and J. A. Kesby, International Association of Hydrological Sciences Publication No. 224, IAHS Press, Wallingford, 1994. No. of pages: x + 498. Price: £75.00. ISBN 0-947571-19-1
  9. Mineral magnetic characterization of sediment sources from an analysis of lake and floodplain sediments in the catchments of the Old Mill reservoir and Slapton Ley, South Devon, UK
  10. Light perception in the vertebrate brain: An ultrastructural analysis of opsin- and vasoactive intestinal polypeptide-immunoreactive neurons in iguanid lizards
  11. Retinal projections in mice with inherited retinal degeneration: Implications for circadian photoentrainment
  12. Axonal connections of the High Vocal Center and surrounding cortical regions in juvenile and adult male zebra finches
  13. Molecular cloning and tissue distribution of an avian D2 dopamine receptor mRNA from the domestic turkey (Maleagris gallopavo)
  14. Toward high-performance computational chemistry: II. A scalable self-consistent field program
  16. Cell proliferation studies in primary synovial chondromatosis
  17. Book Review: Pathology of the Prostate, Volume 34 in the series Major Problems in Pathology, by Christopher S. Foster and David G. Bostwick. W. B. Saunders Company, Philadelphia
  18. Proliferation of parenchymal epithelial cells enhanced in chronic pancreatitis
  19. Decreased HLA-A expression in prostate cancer is associated with normal allele dosage in the majority of cases
  20. Thermal Effects on Net Protein Ratio of Red Kidney Beans (Phaseolusvulgaris L)

8 other products in the same category: